12:00 AM
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Symlin pramlintide acetate: Post-marketing study data

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), San Diego, Calif.
Product: Symlin pramlintide acetate
Business: Endocrine
Molecular target: Amylin receptor
Description: Synthetic amylin analog
Indication: Treat Type II diabetes
Endpoint: Occurrence of primary...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >